ICU Medical, Inc. (ICUI)
NEUTRALFundamental
49
Kurs
$183.10
Marktkapitalisierung
$4.55B
Teil 1 · Was das Unternehmen wert ist
Übersicht
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$2.16B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$30M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$92M
Gesamtes Eigenkapital
$2.12B
Gesamtverbindlichkeiten
$1.93B
Current Ratio
2.43
Zinsdeckungsgrad
0.87
Schulden/EBITDA
5.28
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$102.68
Aktueller Kurs
$183.10
Sicherheitsmarge
-78.3%
Innerer-Wert-Spanne
$66.74 - $138.62
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
153.40
ROE
0.0%
P/B-Verhältnis
2.12
P/FCF
29.87
Bruttomarge
39.1%
ROIC
1.6%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
1.6%
WACC
8.5%
ROIC − WACC
-6.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (14)
- Gross Margin 39.1%
- P/FCF 29.87
- P/B Ratio 2.12
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Revenue Growth 5Y 11.9%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 20.3%
- Earnings Quality (OCF/NI) 7.86
- Share Dilution 0.1%
- Net Margin Trend 1.4% vs -1.6%
- Piotroski F-Score 7/9
Nicht bestanden (12)
- EPS shows upward trend
- EPS CAGR -19.56%
- Price CAGR 2.18%
- ROIC 1.6%
- Operating Margin 3.3%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 2.2%
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienanzahl ist stabil
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Vivek Jain | CEO & Chairman of the Board | 53 |
| Mr. Daniel Woolson | President | 48 |
| Mr. Brian Michael Bonnell | CFO & Treasurer | 51 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 57 |
| Ms. Virginia Ruth Sanzone | Corporate VP, General Counsel, Secretary & Compliance Officer | 50 |
| Ben Sousa | Chief Information Officer | - |
| Olivia Barrall | Vice President of Human Resources | - |
Prüfungsrisiko
5
Vorstandsrisiko
4
Vergütungsrisiko
4
Aktionärsrechterisiko
5
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for ICUI, sourced from Markets Gazette.